Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/rmv.2133

http://scihub22266oqcxt.onion/10.1002/rmv.2133
suck pdf from google scholar
33210457!ä!33210457

suck abstract from ncbi


Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33210457      Rev+Med+Virol 2020 ; 30 (6): 1-13
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Remdesivir: A beacon of hope from Ebola virus disease to COVID-19 #MMPMID33210457
  • Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
  • Rev Med Virol 2020[Nov]; 30 (6): 1-13 PMID33210457show ga
  • Since the emergence of coronavirus disease 2019 (Covid-19), many studies have been performed to characterize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and find the optimum way to combat this virus. After suggestions and assessments of several therapeutic options, remdesivir (GS-5734), a direct-acting antiviral drug previously tested against Ebola virus disease, was found to be moderately effective and probably safe for inhibiting SARS-CoV-2 replication. Finally, on 1 May 2020, remdesivir (GS-5734) was granted emergency use authorization as an investigational drug for the treatment of Covid-19 by the Food and Drug Administration. However, without a doubt, there are challenging days ahead. Here, we provide a review of the latest findings (based on preprints, post-prints, and news releases in scientific websites) related to remdesivir efficacy and safety for the treatment of Covid-19, along with covering remdesivir history from bench-to-bedside, as well as an overview of its mechanism of action. In addition, active clinical trials, as well as challenging issues related to the future of remdesivir in Covid-19, are covered. Up to the date of writing this review (19 May 2020), there is one finished randomized clinical trial and two completed non-randomized studies, in addition to some ongoing studies, including three observational studies, two expanded access studies, and seven active clinical trials registered on the clinicaltrials.gov and isrctn.com websites. Based on these studies, it seems that remdesivir could be an effective and probably safe treatment option for Covid-19. However, more randomized controlled studies are required.
  • |*COVID-19 Drug Treatment[MESH]
  • |Adenosine Monophosphate/*analogs & derivatives/pharmacology/therapeutic use[MESH]
  • |Alanine/*analogs & derivatives/pharmacology/therapeutic use[MESH]
  • |Antiviral Agents/*pharmacology/*therapeutic use[MESH]
  • |COVID-19/*virology[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Ebolavirus/drug effects/physiology[MESH]
  • |Hemorrhagic Fever, Ebola/*drug therapy/*virology[MESH]
  • |Humans[MESH]
  • |SARS-CoV-2/drug effects/physiology[MESH]
  • |Treatment Outcome[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box